LLY
Eli Lilly and Company
LLY has the edge over NEOG overall, supported by stronger fundamentals and lower modeled downside.
NEOG
Neogen Corporation
NEOG's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NEOG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
NEOG's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NEOG PE Valuation
NEOG has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NEOG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for NEOG, with profitability improving. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NEOG on earnings quality, reporting a profit while its opponent remains loss making.
NEOG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.34 | — |
| Q3 2026 | -$0.26 | +$4.54 |
| Q2 2026 | -$0.04 | +$4.99 |
| Q1 2026 | -$2.80 | -$0.57 |
| Q4 2025 | -$2.77 | -$0.58 |
| Q3 2025 | -$4.80 | -$4.69 |
| Q2 2025 | -$5.03 | -$4.99 |
| Q1 2025 | -$2.23 | -22400% |
| Q4 2024 | -$2.19 | -3750% |
NEOG is still losing money, but far less than before: $0.26 per share over the past year, against $5.03 at its worst in mid-2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NEOG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NEOG on profitability, with a higher operating margin.
NEOG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $222.8M | +6.5% |
| Q2 2026 | $225.3M | -0.1% |
| Q1 2026 | $211.2M | -4.4% |
| Q4 2025 | $224.7M | -2.8% |
| Q3 2025 | $209.2M | -3.6% |
| Q2 2025 | $225.5M | -4.8% |
| Q1 2025 | $221M | -3.4% |
| Q4 2024 | $231.3M | +0.7% |
NEOG's revenue grew through 2023 and has held roughly level since: $223M last quarter, up 6.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.8% | +6.9 points |
| Q2 2026 | 1.4% | +273 points |
| Q1 2026 | -1.6% | -4 points |
| Q4 2025 | -2.4% | +195 points |
| Q3 2025 | -7.7% | -8.7 points |
| Q2 2025 | -271% | -277 points |
| Q1 2025 | 2.5% | -2.8 points |
| Q4 2024 | -198% | -204 points |
NEOG's operating margin was −0.8% last quarter, up 6.9 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
NEOG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.7M | +$17.8M |
| Q2 2026 | $26.2M | +6353% |
| Q1 2026 | $11.1M | +$24.6M |
| Q4 2025 | $7.8M | -66% |
| Q3 2025 | -$13.1M | +$43.2M |
| Q2 2025 | $406K | -84% |
| Q1 2025 | -$13.5M | +$48.8M |
| Q4 2024 | $23.1M | +$31.8M |
NEOG's free cash flow has turned positive after four years mostly in the red: $50M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NEOG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NEOG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +600K shares |
| 1 year | +0.4% | +765K shares |
| 3 years | +0.6% | +1.3M shares |
| 5 years | +102% | +110M shares |
| Available history | +106% | +112M shares |
NEOG has 218M diluted shares, about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over NEOG on leverage, with a lower net debt burden relative to earnings.
NEOG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 12.7x | High |
| Q2 2026 | 6.4x | High |
| Q3 2024 | 4.8x | High |
| Q2 2024 | 4.1x | High |
| Q1 2024 | 3.9x | Elevated |
| Q4 2023 | 3.7x | Elevated |
| Q3 2023 | 4.4x | High |
| Q2 2023 | 5.7x | High |
NEOG's net debt is about 13 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NEOG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 25.0 | Neutral |
NEOG's weekly RSI is 51 (neutral) and its Stochastic is 25 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NEOG PE vs Healthcare Sector
| Metric | NEOG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEOG has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NEOG on trend strength, trading above more of its moving averages.
NEOG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 7.3% below |
| 20 week MA | $11.5 | 2.9% below |
| 50 week MA | $10.1 | 11% above |
| 100 week MA | $8.62 | 30% above |
| 200 week MA | $12.9 | 13% below |
NEOG's trend is mixed: it's above two of its five weekly moving averages, and 13% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
NEOG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.5 | $40.5 | +24% |
| 2021 | $40.5 | $44.4 | +9.7% |
| 2022 | $44.4 | $14.9 | -67% |
| 2023 | $14.9 | $20.1 | +35% |
| 2024 | $20.1 | $12.4 | -38% |
| 2025 | $12.4 | $7.13 | -43% |
| 2026 YTD | $7.13 | $11.2 | +57% |
NEOG has the edge over LLY on returns for 2026, with the stronger performance.